Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6
Open Access
- 25 October 2023
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (44) , 12484-12497
Abstract
A covalent peptide ligand mimicking the binding motif in the E6AP protein selectively crosslinks to HPV16 E6 with quantitative conversion. This ‘reactide’ provides a starting point in the development of inhibitors against HPV-driven cancers.Keywords
All Related Versions
This publication has 92 references indexed in Scilit:
- Peptide Interactions Stabilize and Restructure Human Papillomavirus Type 16 E6 To Interact with p53Journal of Virology, 2012
- Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomavirusesProceedings of the National Academy of Sciences, 2012
- Human Papillomavirus: Gene Expression, Regulation and Prospects For Novel Diagnostic Methods and Antiviral TherapiesFuture Microbiology, 2010
- Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancersCancer Gene Therapy, 2010
- Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and TreatmentAnnual Review of Pathology: Mechanisms of Disease, 2009
- Papillomavirus E6 proteinsVirology, 2009
- Design and Characterization of Helical Peptides that Inhibit the E6 Protein of Papillomavirus,Biochemistry, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- In Vivo and in Vitro Binding of Microcystin to Protein Phosphatase 1 and 2ABiochemical and Biophysical Research Communications, 1995
- The cyanobacterial toxin microcystin binds covalently to cysteine‐273 on protein phosphatase 1FEBS Letters, 1995